Abstract
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions. The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells. Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein. This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches.
Keywords: Adhesion, cancer, Focal Adhesion Kinase, inhibitor, metastasis, tumor, Breast Cancer, Hepatocellular Carcinoma, Acute Myeloid Leukemia, HBV, FRNK, Troglitazone, Neuroblastoma, IHC, EGFR
Anti-Cancer Agents in Medicinal Chemistry
Title: Focal Adhesion Kinase as a Cancer Therapy Target
Volume: 10 Issue: 10
Author(s): Vita M. Golubovskaya
Affiliation:
Keywords: Adhesion, cancer, Focal Adhesion Kinase, inhibitor, metastasis, tumor, Breast Cancer, Hepatocellular Carcinoma, Acute Myeloid Leukemia, HBV, FRNK, Troglitazone, Neuroblastoma, IHC, EGFR
Abstract: Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that resides at the sites of at focal adhesions. The 125 kDa FAK protein is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell adhesion, growth, proliferation, survival, angiogenesis and migration, all of which are often disrupted in cancer cells. Normal tissues have low expression of FAK, while primary and metastatic tumors significantly overexpress this protein. This review summarizes expression of FAK by immunohistochemical staining in different tumor types and presents several FAK inhibition therapy approaches.
Export Options
About this article
Cite this article as:
M. Golubovskaya Vita, Focal Adhesion Kinase as a Cancer Therapy Target, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728648
DOI https://dx.doi.org/10.2174/187152010794728648 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
1,4-Benzothiazines-A Biologically Attractive Scaffold
Mini-Reviews in Medicinal Chemistry DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Interactome Analysis of the Differentially Expressed Proteins in Uterine Leiomyoma
Anti-Cancer Agents in Medicinal Chemistry Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer Patients in Low-Resource Settings
Current Women`s Health Reviews Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening Protein-Based HIV-1 Microbicides
Current HIV Research Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design <sup>18</sup>F-DOPA and <sup>18</sup>F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports
Current Radiopharmaceuticals Subject Index to Volume 9
Current Pharmaceutical Design Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Positron Emission Tomography (PET) in the Evaluation of Response to Therapy in Non-Small Cell Lung Cancer
Current Cancer Therapy Reviews Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design